Our timeline of public broadcasting’s history traces its growth from the earliest radio broadcasts to its days as the home of Big Bird, Frontline and Terry Gross. We hit the landmark events, like the ...

Gleevec is a revolutionary drug that has helped transform some blood cancers into chronic illnesses rather than death sentences. Around since 2001, new uses have been found for the drug every few ...

Timeline — previously known as Location History — is the feature that tracks your routes and trips based on your phone’s location, allowing you to revisit all the places you’ve been in the ...

Several years ago, a group of oncologists penned an editorial on drug prices, with Gleevec (imatinib mesylate), the groundbreaking tyrosine kinase inhibitor, as their illustration of egregious ...

In this episode of the “CURE® Talks Cancer” podcast Mel Mann discusses his participation in the clinical trial for Gleevec and how it changed the trajectory of his life. In 1998, Mel Mann received his ...

Novartis ($NVS) has agreed to work with Colombia to lower the price of its cancer drug, Gleevec, to prevent the country from issuing a compulsory license for the med ...

The first Phase III trial to directly compare Novartis’ chronic myeloid leukemia (CML) drugs Tasigna® and Glivec® (known as Gleevec in the U.S.) found Tasigna produced faster and deeper ...

It almost never actually happens. With Gleevec, it did. The once-a-day pill turned chronic myelogenous leukemia, or CML, from a certain death sentence into a manageable disease. Now data shows it ...

How do scientists develop new treatments for disease? With Gleevec, a remarkable cancer drug, the approach was to target the disease at the cellular and subcellular level. When people say Gleevec ...

Average wholesale price of Gleevec per year at 400 mg per day—typical dosing ... as part of a broader strategy for promoting optimal delivery of patient care. A Timeline Leading Up to the First ...

ZURICH, Feb 1 (Reuters) - India's Sun Pharma launched a generic version of Novartis's leukaemia drug Gleevec on Monday in the United States and hopes to poach a third of sales in six months by ...